News & Events

News

Prostate cancer awareness: Doctor talks screenings, misconceptions and more

September 16, 2021

Alfred Winkler, MD, MBA, Chief of Urology at NewYork-Presbyterian Brooklyn Methodist Hospital and NewYork-Presbyterian Lower Manhattan Hospital, discusses prostate cancer screenings, misconceptions, and more.

#ProstateCancerAwarenessMonth

...

Advantages of iTind system for BPH-related LUTS

September 16, 2021

Dr. Bilal Chughtai, Associate Professor of Urology at Weill Cornell Urology and Associate Attending Urologist at NewYork-Presbyterian Hospital, discusses advantages of iTind system for BPH-related LUTS via Urology Times:

https://www.urologytimes.com/view/dr-chughtai-discusses-advantages-of-it...

For more information...

Weill Cornell Urology: Dr. Jim C. Hu - Partial Nephrectomy

August 16, 2021

https://youtu.be/Icr-osMWEYY

If you would like an appointment, please call our office at 646-962-9600. You may alternatively request an appointment via our online form here: ...

"Transperineal Prostate Biopsy Safe, Effective Under Local Anesthesia"

July 21, 2021

"Transperineal Prostate Biopsy Safe, Effective Under Local Anesthesia" featuring Dr. Jim C. Hu, Ronald Lynch Professor of Urologic Oncology at Weill Cornell Urology and...

Retzius-Sparing Radical Prostatectomy - Jim C. Hu, MD of Weill Cornell Urology

June 28, 2021

https://youtu.be/d57oum9s_7Q

Retzius-Sparing Radical Prostatectomy

Jim C. Hu, MD
Ronald P. Lynch Professor of Urologic Oncology
Director of the LeFrak Center for Robotic Surgery
Quality and Patient Safety Chair

To learn more about Dr. Hu, please visit: https://urology.weillcornell.org/jim-c-hu

To learn more about urologic conditions, please visit...

Pivotal data published for sacituzumab govitecan in bladder cancer

May 12, 2021

“Sacituzumab govitecan is an active drug with a manageable safety profile with most common toxicities of neutropenia and diarrhea. Sacituzumab govitecan has notable efficacy compared with historical controls in pretreated mUC that has progressed on both prior platinum-based chemotherapy regimens and checkpoint inhibition,” principal investigator Scott T. Tagawa, MD, MS, FACP, professor of Medicine and Urology at Weill Cornell Medicine, an oncologist at New York-Presbyterian/Weill...

"Minimally Invasive Surgery on the Outs for Cervical Cancer?"

April 30, 2021

"Minimally Invasive Surgery on the Outs for Cervical Cancer?" featuring Patrick Lewicki, MD, of NewYork-Presbyterian Hospital and Weill Cornell Urology on medpagetoday.

https://www.medpagetoday.com/...

Dr. Massimo Loda of Weill Cornell Pathology and Dr. Jim C Hu of Weill Cornell Urology/ NewYork-Presbyterian Hospital awarded the Prostate Cancer Foundation Special Challenge Award.

April 23, 2021

This award funds cross-disciplinary teams of investigators in strategic areas to help support transformational prostate cancer research to accelerate progress towards the reduction of death and suffering due to recurrent or advanced prostate cancer.

For more info on the Prostate Cancer Foundation, visit: https://www.pcf.org/

ASPIRE 2021: New Focus on Male Factors Critical for Success in Human Fertility Treatment - Dr. Peter N. Schlegel

April 22, 2021

The adverse impact of male factors in assisted reproductive treatments will be brought into a sharp and disturbing focus at the 10th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) this week.

The ASPIRE Congress, originally to be held in the Philippines, is being presented in virtual format to on-line participants in more than 100 countries because of ongoing concerns about COVID-19.

...

Practice Update - Dr. Peter N. Schlegel Comments on the Impact of the Microbiome on Infertility Patients

April 22, 2021

Practice Update, 04/21/2021 - The microbiome has been studied in a wide variety of illnesses and medical conditions, including urologic disorders. The microbiome refers to all bacteria,...